Pharmacokinetics Study of Liposomal Paclitaxel in Humans

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether there is any difference of the pharmacokinetics of two taxane formulations, paclitaxel injection and liposomal paclitaxel in Chinese cancer patients with solid tumors.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shandong Luye Pharmaceutical Co., Ltd.
• Collaborator: Nanjing Sike Pharmaceutical Co., Ltd.
• Treatments: Albumin-Bound Paclitaxel; Paclitaxel

Criteria

Inclusion Criteria:

• Eligible patients must have histologically confirmed solid tumors of advanced stages

• Patients who are suitable for being treated with liposomal paclitaxel only

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2

• Patients who are expected to be alive for at least 3 months

• Adequate hematologic, hepatic and renal functions

• Adequate other organ functions as defined by the protocol

• No prior systemic chemotherapy at least 4 weeks before the recruitment

• No previous anaphylactic reaction to hormone.

Exclusion Criteria:

• Allergy to any study medication

• Serious complication that would compromise the patient's ability to complete the study

• Grade ≥1 neuropathy using NCI CTCAE version 3.0 criteria

• Pregnancy or breast feeding